Loading...
•
Dec 31, 2024
Incyte Q4 2024 Earnings Report
Key Takeaways
Incyte reported strong fourth-quarter 2024 results, with total revenues increasing 16% year-over-year to $1.18 billion. Growth was primarily driven by Jakafi ($773M, +11% YoY) and Opzelura ($162M, +48% YoY). GAAP net income remained stable at $201M, while non-GAAP net income rose 18% to $281M. GAAP diluted EPS was $1.02, and non-GAAP diluted EPS was $1.43.
Incyte
Incyte
Incyte Revenue by Segment
Incyte Revenue by Geographic Location
Revenue by Segment
Jakafi Revenue
CapyFin.comIclusig Revenue
CapyFin.comOpzelura Revenue
CapyFin.comPemazyre Revenue
CapyFin.comZynyz Revenue
CapyFin.comRevenue by Geographic Location
Jakavi Royalty Revenue
CapyFin.comOlumiant Royalty Revenue
CapyFin.comTabrecta Royalty Revenue
CapyFin.com Forward Guidance
Incyte expects continued revenue growth in 2025, driven by increased Jakafi and Opzelura sales, alongside pipeline advancements.
Positive Outlook
- Jakafi revenue expected to grow to $2.925B - $2.975B in 2025
- Opzelura revenue guidance increased to $630M - $670M
- Four new product launches planned in 2025
- Expansion of Opzelura in pediatric atopic dermatitis
- R&D milestones including pivotal study readouts and Phase 3 initiations
Challenges Ahead
- Increased R&D expenses impacting profitability
- Higher SG&A costs due to commercial expansion
- Potential competition in the JAK inhibitor market
- Regulatory uncertainties for new product approvals
- Foreign exchange fluctuations affecting revenues
Revenue & Expenses
Visualization of income flow from segment revenue to net income